GE, Lantheus launch phase III trial for flurpiridaz

By staff writers

July 31, 2018 -- GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.

Called the AURORA study, the international multicenter trial will evaluate the diagnostic efficacy of flurpiridaz F-18 injection PET myocardial perfusion imaging (MPI) for detecting coronary artery disease (CAD). The prospective, open-label study will enroll patients with suspected CAD for whom an intracoronary angiography has been indicated. These patients will undergo SPECT MPI and flurpiridaz F-18 injection PET MPI prior to receiving coronary angiography.

The study's primary end point will be the diagnostic performance of flurpiridaz F-18 injection PET MPI for detecting significant CAD, according to the vendors. The first patient was enrolled in June, and a total of 650 will be included in the trial. The companies project that the last patient follow-up will be completed in August 2020.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking